|
|
|
Insider
Information: |
Thompson Peter A |
Relationship: |
Director |
City: |
Bellevue |
State: |
WA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
12 |
|
Direct
Shares |
385,419 |
|
Indirect Shares
|
39,061,451 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$128,542,673 |
|
|
Total
Shares |
39,446,870 |
|
|
Total
Value |
$128,542,673 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
4
|
Stock
price went up :
|
1
|
2
|
Stock
price went down : |
1
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
19.0%
|
340.9%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Trubion Pharmaceuticals, Inc |
TRBN |
President and CEO, Dir... |
2009-05-22 |
385,419 |
2009-05-22 |
1,000 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director |
2015-07-21 |
0 |
2015-07-21 |
1,989,949 |
Premium* |
|
Adaptimmune Therapeutics PLC |
ADAP |
Director |
|
0 |
2018-06-06 |
4,901,310 |
Premium* |
|
Corvus Pharmaceuticals, Inc. |
CRVS |
Director, 10% Owner |
2016-03-29 |
0 |
2021-09-20 |
6,943,654 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2017-07-24 |
0 |
2024-05-18 |
0 |
Premium* |
|
Synthorx, Inc. |
THOR |
Director, 10% Owner |
2018-12-11 |
0 |
2020-01-23 |
0 |
Premium* |
|
Prevail Therapeutics Inc. |
PRVL |
Director, 10% Owner |
|
0 |
2021-01-22 |
0 |
Premium* |
|
Pmv Pharmaceuticals, Inc. |
PMVP |
Director, 10% Owner |
2020-09-29 |
0 |
2020-09-29 |
114,039 |
Premium* |
|
Silverback Therapeutics, Inc. |
SBTX |
Director |
|
0 |
2023-08-29 |
9,240,887 |
Premium* |
|
Decibel Therapeutics, Inc. |
DBTX |
Director, 10% Owner |
2021-02-17 |
0 |
2021-02-17 |
883,418 |
Premium* |
|
Edgewise Therapeutics, Inc. |
EWTX |
Director, 10% Owner |
|
0 |
2024-01-23 |
14,756,096 |
Premium* |
|
Janux Therapeutics, Inc. |
JANX |
Director |
2021-12-16 |
0 |
2021-12-29 |
231,098 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
72 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TRBN |
Trubion Pharmaceuticals, ... |
President, CEO & TreasurerOffi |
|
2006-10-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
254,032 |
|
- |
|
TRBN |
Trubion Pharmaceuticals, ... |
President and CEO |
|
2006-10-18 |
4 |
B |
$13.00 |
$13,000 |
I/I |
1,000 |
255,032 |
2.58 |
- |
|
TRBN |
Trubion Pharmaceuticals, ... |
President and CEO |
|
2007-11-19 |
4 |
B |
$9.84 |
$50,289 |
D/D |
5,000 |
259,032 |
2.81 |
- |
|
TRBN |
Trubion Pharmaceuticals, ... |
President and CEO |
|
2009-05-22 |
4 |
OE |
$0.31 |
$39,622 |
D/D |
126,387 |
385,419 |
0 |
- |
|
SRRA |
Sierra Oncology Inc |
Director |
|
2015-07-21 |
4 |
B |
$17.00 |
$2,975,000 |
I/I |
175,000 |
1,989,949 |
2.1 |
- |
|
SRRA |
Sierra Oncology Inc |
Director |
|
2015-07-21 |
4 |
A |
$5.22 |
$464,964 |
I/I |
89,159 |
1,814,949 |
0 |
- |
|
SRRA |
Sierra Oncology Inc |
Director |
|
2015-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
1,725,790 |
1,725,790 |
0 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
28,041,004 |
|
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
4,708,450 |
4,708,450 |
0 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-03-29 |
4 |
B |
$15.00 |
$8,250,000 |
I/I |
550,000 |
5,258,450 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-05-18 |
4 |
B |
$11.55 |
$48,510 |
I/I |
4,200 |
5,262,650 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-05-19 |
4 |
B |
$12.11 |
$31,525 |
I/I |
2,600 |
5,265,250 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-05-20 |
4 |
B |
$13.09 |
$61,732 |
I/I |
4,716 |
5,269,966 |
2.25 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2016-05-20 |
4 |
B |
$10.04 |
$24,096 |
I/I |
2,400 |
28,043,404 |
2.1 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2016-05-23 |
4 |
B |
$10.40 |
$12,392,640 |
I/I |
1,191,600 |
29,235,004 |
2.1 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2016-05-24 |
4 |
B |
$10.48 |
$5,432,832 |
I/I |
518,400 |
29,753,404 |
2.1 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-09 |
4 |
B |
$12.95 |
$388,500 |
I/I |
30,000 |
5,299,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-10 |
4 |
B |
$12.98 |
$259,600 |
I/I |
20,000 |
5,319,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-14 |
4 |
B |
$12.71 |
$127,100 |
I/I |
10,000 |
5,329,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-15 |
4 |
B |
$11.94 |
$59,700 |
I/I |
5,000 |
5,334,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-16 |
4 |
B |
$12.04 |
$60,200 |
I/I |
5,000 |
5,339,966 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-17 |
4 |
B |
$12.48 |
$153,504 |
I/I |
12,300 |
5,352,266 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-21 |
4 |
B |
$12.87 |
$335,688 |
I/I |
26,083 |
5,378,349 |
2.25 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-23 |
4 |
B |
$12.92 |
$1,292 |
I/I |
100 |
5,378,449 |
2.17 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
Director |
|
2016-06-24 |
4 |
B |
$12.99 |
$11,691 |
I/I |
900 |
5,379,349 |
2.17 |
- |
|
72 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|